Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with significant revenue and EPS growth. The company raised its revenue guidance and demonstrated confidence in continued growth, especially with LUPKYNIS. Although there were some uncertainties regarding FDA requests, the overall sentiment remains positive due to the raised guidance and strong financial metrics. The Q&A section reinforced positive trends and growth potential, contributing to a positive stock price prediction.
Key Financial Performance
Total Revenue (Q3 2025) $73.5 million, up 8% from $67.8 million in Q3 2024. Excluding a $10 million milestone payment in 2024, total revenue increased by 27% year-over-year. The increase is attributed to the growth in LUPKYNIS sales.
Net Product Sales of LUPKYNIS (Q3 2025) $70.6 million, up 27% from $55.5 million in Q3 2024. The growth is due to continued momentum following its inclusion in lupus nephritis treatment guidelines.
Net Income (Q3 2025) $31.6 million, up 119% from $14.4 million in Q3 2024. The increase is driven by higher revenue and operational efficiencies.
Diluted Earnings Per Share (Q3 2025) $0.23, up 130% from $0.10 in Q3 2024. The growth reflects increased net income.
Cash Flows from Operating Activities (Q3 2025) $44.5 million, up 162% from $17 million in Q3 2024. The increase is due to improved operational performance and higher revenue.
Total Revenue (9 months ended September 30, 2025) $205.9 million, up 17% from $175.3 million in the same period of 2024. Excluding a $10 million milestone payment in 2024, total revenue increased by 25% year-over-year, driven by LUPKYNIS sales growth.
Net Product Sales of LUPKYNIS (9 months ended September 30, 2025) $197.2 million, up 24% from $158.6 million in the same period of 2024. The increase is attributed to sustained sales momentum.
Net Income (9 months ended September 30, 2025) $76.4 million, up 1,677% from $4.3 million in the same period of 2024. The significant growth is due to higher revenue and operational efficiencies.
Diluted Earnings Per Share (9 months ended September 30, 2025) $0.55, up 1,733% from $0.03 in the same period of 2024. The increase reflects the substantial rise in net income.
Cash Flows from Operating Activities (9 months ended September 30, 2025) $90 million, up 529% from $14.3 million in the same period of 2024. The growth is driven by improved operational performance and higher revenue.
Cash, Cash Equivalents, Restricted Cash, and Investments (as of September 30, 2025) $351.8 million, compared to $315.1 million as of June 30, 2025, and $358.5 million as of December 31, 2024. The change reflects cash flow dynamics and operational activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
LUPKYNIS sales growth: Sales grew 27% year-over-year in Q3 2025, leading to an increase in 2025 sales guidance to $265-$270 million.
Aritinercept development: Advancing toward clinical studies in two autoimmune diseases by the end of 2025, following positive Phase I results.
LUPKYNIS inclusion in guidelines: Momentum driven by inclusion in the American College of Rheumatology lupus nephritis treatment guidelines.
Revenue growth: Total revenue for Q3 2025 was $73.5 million, up 8% from Q3 2024, excluding a one-time milestone, revenue increased 27%.
Net income growth: Net income for Q3 2025 was $31.6 million, up 119% from Q3 2024.
Cash flow improvement: Cash flows from operating activities were $44.5 million in Q3 2025, up 162% from Q3 2024.
Share repurchase program: Repurchased 12.2 million shares for $98.2 million, reducing diluted shares outstanding from 149.8 million to 138.2 million.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Legal Risks: Aurinia Pharmaceuticals has filed a legal complaint against Dr. George Tidmarsh regarding statements about voclosporin. This ongoing legal matter could pose reputational and financial risks to the company.
Regulatory Risks: The company is engaging with the FDA regarding new analyses of LUPKYNIS clinical studies. Any unfavorable feedback or additional regulatory requirements could delay or impact the product's market performance.
Product Safety and Efficacy Risks: While LUPKYNIS has shown robust efficacy and safety, the presence of antidrug antibodies (ADAs) in aritinercept trials, even though not associated with adverse effects, could raise concerns in future studies or regulatory reviews.
Market Competition: Aritinercept, targeting autoimmune diseases, faces competition from existing treatments like Benlysta. Its success depends on demonstrating superior efficacy and safety.
Strategic Execution Risks: The company plans to initiate clinical studies for aritinercept in two autoimmune diseases by the end of 2025. Delays or challenges in executing these plans could impact strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
LUPKYNIS Sales Guidance for 2025: The company has raised its LUPKYNIS sales guidance for 2025 to a range of $265 million to $270 million, reflecting continued momentum and growth.
Total Revenue Guidance for 2025: The company has increased its total revenue guidance for 2025 to a range of $275 million to $280 million, up from the previous range of $260 million to $270 million.
Aritinercept Clinical Development: Aurinia plans to initiate clinical studies of aritinercept in two autoimmune diseases by the end of 2025, with further development details to be disclosed in early 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: For the 9 months ended September 30, 2025, the company repurchased 12.2 million shares for $98.2 million and diluted shares outstanding were reduced from 149.8 million to 138.2 million.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide metrics around prescriber habits for LUPKYNIS and its use versus Gazyva?
A:Management highlighted consistent growth in rheumatology prescribers, driven by a sharpened commercial focus on high-volume prescribers and the positive impact of ACR guidelines. They noted that LUPKYNIS is perceived as complementary to B-cell treatments like Gazyva and Benlysta, with faster goal achievement and steroid tapering benefits.
Q:What trends are you seeing in Q4 and your confidence in continued growth, especially considering Roche's recent approval?
A:Management expressed confidence in continued growth, supported by positive momentum and raised guidance for the year. They did not see any inconsistencies in trends moving into Q4.
Q:What updates can you provide on the APRIL/BAFF program, including selected indications and trial design?
A:Management plans to disclose more details in early 2026. They emphasized strategic considerations like APRIL/BAFF's role in diseases, unmet medical needs, market size, and probability of success.
Q:Is there anything notable from ASN this year?
A:Management mentioned a couple of presentations on real-world use of LUPKYNIS but noted nothing particularly notable from their perspective.
Q:What triggered the FDA information request, and is it related to Tidmarsh issues?
A:Management did not specify the trigger but emphasized that the data disclosed was favorable, showing a 53% reduction in risk of renal-related events or death. They noted that the FDA can ask questions at any time.
Q:Can you clarify if you're in a MAD phase with healthy volunteers for aritinercept?
A:Management confirmed they are in the process and would need to be in that phase to meet their objectives.
Q:Do you expect a response from the FDA regarding the information request?
A:Management cannot predict if the FDA will have more questions but reiterated that their response was favorable.
Q:Can you provide more information on the process of selecting indications for AUR200?
A:Management considers APRIL/BAFF's role in diseases, unmet needs, market size, and probability of success. They plan to disclose more details in 2026.
Q:What are the possible risks to achieving strong Q4 performance, and what is the impact of ACR guidelines?
A:Management noted that physician treatment behaviors take time to change, but they see positive momentum from ACR guidelines. They provided a guidance range of $265-$270 million for the year and did not comment further on risks.
Q:Are you considering non-kidney indications for the BAFF/APRIL program?
A:Management acknowledged the potential for APRIL/BAFF inhibitors in multiple diseases and emphasized their focus on rheumatology and nephrology while not ruling out other areas.
Q:Are you seeing positive trends in patient persistence with LUPKYNIS?
A:Management observed upward trends in persistence, attributed to data showing safety and efficacy over three years and biopsy sub-study results.
Q:Which dose levels are being considered for aritinercept in clinical trials?
A:Management indicated that 150 mg and higher doses are viable and will be explored in multiple ascending dose studies. They plan to disclose more details in 2026.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about the specific trigger for the FDA information request and the exact dose levels for aritinercept clinical trials, citing plans to disclose more details in 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADAs
Aritinercept
Aurinia
District
FDA approval
Greg
Japan milestone
LUPKYNIS analysis
LUPKYNIS approval
LUPKYNIS income
LUPKYNIS reduction
LUPKYNIS sale
activity month
analysis LUPKYNIS
approval Japan
aritinercept
complaint
domain
event death
flow activity
information request
injection site
milestone period
milligram
momentum
payment LUPKYNIS
plasma cell
reduction risk
response
risk event
safety
share cash
site reaction
slide
subject
treatment event
AUPH Transcript
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call shows strong financial performance with significant revenue growth, increased cash flow, and substantial net income improvements. Positive factors include raised guidance, successful LUPKYNIS sales, and a substantial share repurchase plan. Despite some concerns in the Q&A about unclear management responses and terminated studies, overall sentiment remains positive due to strong financial metrics and optimistic future guidance.
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reveals strong financial performance with significant revenue and EPS growth. The company raised its revenue guidance and demonstrated confidence in continued growth, especially with LUPKYNIS. Although there were some uncertainties regarding FDA requests, the overall sentiment remains positive due to the raised guidance and strong financial metrics. The Q&A section reinforced positive trends and growth potential, contributing to a positive stock price prediction.
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript
Positive7-31
The earnings call summary highlights strong financial performance, including significant revenue growth, improved margins, and a notable increase in net income. The company also announced a share repurchase program, which is generally viewed favorably by investors. Despite management's reluctance to provide specific guidance on certain R&D projects, the overall sentiment from the earnings call is positive, supported by raised guidance and improved financial health. The Q&A section did not reveal any major concerns that would significantly offset the positive financial results and strategic initiatives.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript
Positive5-13
The earnings call presents a strong financial performance with a 24% revenue increase and a transition to net income, alongside a robust gross margin. The share repurchase program indicates confidence in the stock. Despite potential challenges like supply chain issues and patent litigation, the optimistic guidance and strategic focus on growth drivers are positive. The Q&A highlights management's proactive approach to market dynamics, suggesting stability and potential growth. Given these factors, the stock is likely to see a positive movement, with a potential increase of 2% to 8% over the next two weeks.
AUPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
